DR Congo rolls out Ebola vaccine for health workers as death toll rises
Health workers in parts of the Democratic Republic of the Congo have begun receiving the Ervebo Ebola vaccine as authorities seek to protect frontline staff amid the countrys fastest-growing outbreak. The campaign, starting in Bunia in Ituri province, will inject about 50,000 frontline workers and monitor 20,000 recipients for up to a year to assess protection against the Bundibugyo strain.
Why It Matters
The rollout represents a major public-health intervention during an outbreak that has no licensed vaccine for the current strain and has caused thousands of cases and deaths; monitoring vaccinated workers could provide evidence on whether an existing vaccine for a different Ebola strain offers cross-protection. Backing from WHO and MSF and use under a compassionate-use programme underline the urgency and provisional nature of the response.
Key Facts
- Vaccine recipients planned: 50,000 frontline health and other workers
- Clinical monitoring cohort: 20,000 recipients to be monitored for up to one year
- Rollout start location and timing: Bunia, capital of Ituri province; rollout began on Saturday
- Targeted provinces: Ituri and North Kivu
- Vaccine used: Ervebo (developed for the Zaire Ebola strain)
Health workers in northeastern Democratic Republic of the Congo have started receiving the Ervebo vaccine as part of a campaign aimed at protecting those engaged in the Ebola response. The rollout began in Bunia, the capital of Ituri province, which authorities identify as the epicentre of the countrys rapidly expanding outbreak. Provincial governor Major-General Gaby Kasongo Mulumba highlighted the particular exposure of healthcare teams involved in containment efforts.
The operation, supported by the World Health Organization and Doctors Without Borders (MSF), will cover Ituri and North Kivu provinces. Officials plan to administer Ervebo to some 50,000 frontline staff. Because Ervebo was developed for the Zaire strain of Ebola, health authorities will monitor 20,000 vaccine recipients for up to one year to assess any effectiveness against the current outbreak strain, identified as Bundibugyo.
Congolese task-force official Steve Ahuka said it is not yet known how well Ervebo might protect against the Bundibugyo virus. WHO experts have pointed to early, mainly animal-data findings that suggest the vaccine could offer some protection, and in August the WHO approved 70,000 doses of Ervebo for use in the DRC. Use in this outbreak is taking place under a compassionate-use programme, which permits deployment of a medical product in a serious situation even when it has not been specifically licensed for that use.
The governments figures show the outbreak has killed at least 3,639 people and infected about 7,541 since May, with 1,823 recoveries reported. While WHO officials have cited "encouraging signs" that transmission may be slowing, MSF warned there is no clear evidence the epidemic is under control. At frontline sites, some health workers said vaccination was mandatory or strongly encouraged as part of the response measures.
Keep Reading
Iran war live: Tehran sets terms for peace; Saudi forces foil Riyadh attack
Trump’s MAGA Inc. funnels another $5 million into Texas Senate race
Michelle Bachelet exits UN chief race after low poll support
